Soleo Health has been named the exclusive in-network specialty pharmacy for Qfitlia (fitusiran) by Sanofi, the first ...

In 2025, Plozasiran (Arrowhead Pharmaceuticals), Donidalorsen (Ionis Pharmaceuticals) and Fitusiran (Sanofi/Alnylam) are expected to receive approval. All of that is being driven by increasing ...

OmniAb, Inc. will report financial results for the three months ended March 31, 2025 after the close of the U.S. financial markets on Thursday, May 8, 2025, and will hold a conference call that same ...

Saisei Ventures, a leading venture investment firm focused on advancing Japanese biotechnology and therapeutic innovations, today announced the launch of its Executive Fellows Program, a structured ...

Fitusiran is being developed for haemophilia A and B in partnership with RNA interference (RNAi) specialist Alnylam – but has already been affected by safety issues.

First up is Alnylam-partnered RNAi candidate fitusiran, an antithrombin-targeting agent in development as a treatment for haemophilia A and B with as few as six injections per year, making it a ...

Fitusiran, which is in phase III clinical trial for hemophilia; cemdisiran that is in phase III clinical trial for Myasthenia Gravis and paroxysmal nocturnal hemoglobinuria, and geographic atrophy ...

The US Food and Drug Administration granted clearances for testing instruments, a blood clot drug companion diagnostic test, and infectious disease tests, among other devices.